Nexus Drug Patent Portfolio
Nexus owns 1 orange book drug protected by 5 US patents Given below is the list of Nexus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090278 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11241400 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11464752 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11478436 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11571398 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
Latest Legal Activities on Nexus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nexus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11464752 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11241400 |
|
Email Notification
Critical
| 14 Jun, 2023 | US11478436 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11478436 |
|
Email Notification
Critical
| 14 Jun, 2023 | US11241400 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11478436 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11464752 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Email Notification
Critical
| 14 Jun, 2023 | US11464752 |
|
Email Notification
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11241400 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Electronic Review
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
|
Email Notification
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
Nexus's Family Patents
Recently granted tentative Approvals to Nexus
These tentative approvals reflect continued regulatory progress across both innovative and generic submissions related to Nexus's portfolio.
Generic tentative approvals
| Drug Name | Active Ingredient | Submission Type | Submission Category | Submission Date |
|---|---|---|---|---|
| Minocycline Hydrochloride | Minocycline Hydrochloride |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | (Not Available) | 12 Jun, 2025 |
Explore deeper patents analysis
Nexus Drug List
Given below is the complete list of Nexus's drugs and the patents protecting them.
1. Emerphed
Emerphed is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090278 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
| US11241400 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
| US11464752 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
| US11478436 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
| US11571398 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emerphed's drug page